https://www.selleckchem.com/products/OSI-906.html
To assess the long-term effects of intraocular bevacizumab (Avastin) injections as an adjunctive drug to manage patients with neovascular glaucoma (NVG). A retrospective study was conducted consisting of 34 eyes with secondary NVG caused by proliferative diabetic retinopathy ( =25), ischemic central retinal vein occlusion ( =8), and retinal ischemia resulting from persistent detachment ( =1) were managed by intraocular injections of bevacizumab (1.25 mg/0.05 mL), in addition to other treatments. The main outcome measure was the change i
Like
Comment
Share
